Table 1. Baseline characteristics of the included studies in the systematic review and meta-analysis of the relationship between T. gondii infection and RA patients.
| No | First author | Publication year | Place of study | Type of study | Method | Test | Results | Age | Sex |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Shapira Y [14] | 2012 | Europe | Case control | BioPlex 2200 system | IgG IgM | Significant | ---- | ---- |
| 2 | Shapira Y [14] | 2012 | Latin America | Case control | BioPlex 2200 system | IgG IgM | Not significant | ---- | ---- |
| 3 | Fischer S [16] | 2013 | Europe | Cross sectional | Chemi luminescence | IgG | Significant | P: 40–74 C:-- | ---- |
| 4 | Kuba RH [27] | 2014 | Iraq (Treated patients) | Case control | ELISA | IgG IgM | Significant | P: 20–80 C:-- | ---- |
| 5 | Kuba RH [27] | 2014 | Iraq (Untreated patients) | Case control | ELISA | IgG IgM | Significant | 20–80 C:-- | ---- |
| 6 | Al kalaby RF [22] | 2016 | Iraq | Case control | ELISA | IgG IgM | Significant | P: 16–50 C: 16–50 | F |
| 7 | El-Sayed NM [25] | 2016 | Egypt | Case control | EIA | IgG IgM | Significant | P: 30–58 C: 29–57 | P: (F:70, M:30) C: (F:34, M:16) |
| 8 | Flegr J [26] | 2016 | Czech and Slovak | cohort | ELISA CFT | IgG IgM | Significant | ---- | P: (F:10, M:3) C: (F:935, M:372) |
| 9 | El- Henawy AA [24] | 2017 | Egypt | Cross sectional | ELISA | IgG IgM | Significant | P: <60 C: <60 | P: (F:29, M:31) C: (F:28, M:32) |
| 10 | Tian A-L [28] | 2017 | China | Case control | ELISA | IgG IgM | Significant | ---- | P: (—) C: (F:454, M:366) |
| 11 | Al- Oqaily MA [23] | 2017 | Iraq | Case control | ELISA | IgG IgM | Significant | P: 13–68 C: 13–68 | ---- |
Age is in years, ELISA: enzyme-linked immunosorbent assay, EIA: enzyme immunoassay, CFT: complement fixation test, IgG: Immunoglobulin G, IgM: Immunoglobulin M, P: Patient, C: Control, F: Female, M: Male